News Releases



AACR to Co-host 2014 Turning the Tide Against Cancer National Conference2541778/26/2014 6:52:54 PM77 Releases/AllItems.aspx586False2014-08-26T04:00:00Z<div class="ExternalClass8461C5384D424BFBBA25BC9BAC3C97D3"><p>​PHILADELPHIA — The American Association for Cancer Research (AACR), the Personalized Medicine Coalition, and Feinstein Kean Healthcare are convening the second national conference on <a href="http&#58;//" target="_blank">Turning the Tide Against Cancer Through Sustained Medical Innovation</a> which will be held 8&#58;30 a.m. to 4 p.m., Oct. 9, at the Knight Conference Center at the Newseum in Washington, D.C. <br><br>The conference will continue the dialogue on patient-centered cancer research and care and will discuss potential policy solutions that align with scientific advances and support innovation while addressing the issue of rising health care costs. It will engage the broader stakeholder community to help identify specific policy pathways aimed at supporting the shift to patient-centered cancer research and care and addressing the value and cost of cancer care.<br><br><a href="https&#58;//;oseq=&amp;c=&amp;ch=&amp;zbrandid=4017&amp;zidType=CH&amp;zid=24287158&amp;zsubscriberId=1056828440&amp;zbdom=http&#58;//" target="_blank">Register</a> for the conference, which is free to members of the press.<br><br><a href="http&#58;//;siteid=aacrjnls&amp;ijkey=6zXz3V7qFG.d6%29." target="_blank">Read</a> the 2014 Turning the Tide Against Cancer paper published in Clinical Cancer Research, a journal of the AACR.<br><br><a href="http&#58;//" target="_blank">Learn more</a> about Turning the Tide Against Cancer initiative.<br><br><a href="http&#58;//;zidType=CH&amp;zid=24287161&amp;zsubscriberId=1056828440&amp;zbdom=http&#58;//" target="_blank">View the agenda</a> for featured panels, sessions, and speakers.</p></div>
Cigarettes With Reduced Nicotine May Not Increase Smoking Intensity2436088/22/2014 1:47:08 PM90 Releases/AllItems.aspx585False2014-08-22T04:05:00Z<div class="ExternalClass3669D791C0314ECE9D7CCE4A3B9DC41C"><p>​PHILADELPHIA — Adults who smoked reduced-nicotine cigarettes did not smoke with more intensity to compensate for the lower levels of nicotine, and therefore were not exposed to more toxic chemicals, according to a study published in <a href="http&#58;//" target="_blank">Cancer Epidemiology, Biomarkers &amp; Prevention</a>, a journal of the American Association for Cancer Research.</p><p><img src="/PublishingImages/Hammond_David_150x200.jpg" alt="" style="margin&#58;5px 20px;vertical-align&#58;auto;float&#58;right;" />&quot;As a result of the 2009 Tobacco Act, the U.S. Food and Drug Administration [FDA] has the mandate to reduce nicotine levels in cigarettes to negligible amounts,&quot; said <a href="https&#58;//" target="_blank">David Hammond, PhD</a>, associate professor in the School of Public Health and Health Systems of the <a href="https&#58;//" target="_blank">University of Waterloo</a> in Ontario, Canada.</p><p>&quot;One of the primary barriers to doing so has been a concern that individuals who continue to smoke will be exposed to greater amounts of toxic chemicals in smoke as they try to extract more nicotine from cigarettes,&quot; explained Hammond. &quot;The current study suggests that this may not be the case.</p><p>&quot;Our study suggests that smokers are unable or unwilling to compensate when there is markedly less nicotine in the cigarette and when the experience of smoking is far less rewarding. Our study may help regulators anticipate the possible consequences of mandatory nicotine reductions in cigarettes,&quot; said Hammond.</p><p>Hammond and colleagues recruited to the study 72 adult smokers, ages 18 to 65, 42 female and 30 male. After completing a smoking history and demographic data survey, participants smoked their usual brand of cigarettes for one week. During the next three weeks, they smoked Quest 1, Quest 2, and Quest 3 cigarettes, in that sequence, one brand a week. Participants provided urine and breath samples at the end of each week.</p><p>Quest 1, Quest 2, and Quest 3 cigarettes have nicotine emission levels of 0.6 mg, 0.3 mg, and 0.05 mg or less, respectively, as opposed to about 1.2 mg in regular cigarettes.</p><p>At the end of the study, the researchers found no difference in the number of cigarettes used by the participants, irrespective of the brand; no difference in the number of puffs they took from different brands; no difference in the amount of post-cigarette carbon monoxide levels in their breath; and no difference in urine levels of 1-hydroxypyrene, a chemical in cigarettes with cancer-causing potential.</p><p>Cotinine, a breakdown product of nicotine often measured to estimate nicotine levels, however, fell by 34 percent and 55 percent in the participants' urine, after smoking Quest 2 and Quest 3 cigarettes, respectively.</p><p>About 44 percent of the study participants reported smoking non-Quest cigarettes during the Quest 3 study period.</p><p>This study was funded by the Health Canada Tobacco Control Program, a Canadian Institutes of Health Research New Investigator Award, and a Canadian Cancer Society Research Institute Junior Investigator Award. Hammond declares no conflicts of interest.</p></div>
AACR Invites Nominations for 2015 Team Science and Immunology Awards2312338/18/2014 1:40:46 PM70 Releases/AllItems.aspx583False2014-08-15T04:00:00Z<div class="ExternalClass67263F9D0E4B415693820B0AA62C5141"><p>​PHILADELPHIA — The American Association for Cancer Research (AACR) announces a call for nominations for the Ninth Annual AACR Team Science Award and the Third Annual AACR-<a target="_blank" href="http&#58;//">Cancer Research Institute</a> (CRI) Lloyd J. Old Award in Cancer Immunology.<br><br>The awards will be presented during the <a href="/Meetings/Pages/MeetingDetail.aspx?EventItemID=25">AACR Annual Meeting 2015</a>, which will be held April 18-22, in Philadelphia.<br><br><strong><a href="/Research/Awards/Pages/Awards-Detail.aspx?ItemId=8">Ninth Annual AACR Team Science Award</a></strong><br><br>The AACR Team Science Award was established to acknowledge and catalyze the growing importance of interdisciplinary teams to the understanding of cancer and/or the translation of research discoveries into clinical cancer applications. The award will recognize an outstanding interdisciplinary research team for its innovative and meritorious science that has advanced or likely will advance our fundamental knowledge of cancer or a team that has applied existing knowledge to advance the detection, diagnosis, prevention or treatment of cancer.<br><br>The team selected to receive the AACR Team Science Award will collectively be awarded an honorarium of $50,000.<br><br>Last year’s award was presented to the <a href="/Newsroom/Pages/News-Release-Detail.aspx?ItemID=472">Duke University/Johns Hopkins University/National Cancer Institute Malignant Brain Tumor Team</a>, led by Darell Doty Bigner, MD, PhD, director of the Preston Robert Tisch Brain Tumor Center and the Pediatric Brain Tumor Foundation Institute at Duke University School of Medicine.<br><br>The Ninth Annual AACR Team Science Award is generously supported by Eli Lilly and Company.<br><br><strong><a href="/Research/Awards/Pages/Awards-Detail.aspx?ItemId=2">Third Annual AACR-CRI Lloyd J. Old Award in Cancer Immunology</a></strong><br><br>The AACR-CRI Lloyd J. Old Award in Cancer Immunology was established to honor the memory of the late Lloyd J. Old and will recognize an active scientist whose outstanding and innovative research in cancer immunology has had a far-reaching impact on the cancer field. <br><br>Last year’s honoree was <a href="/Pages/News-Release-Detail.aspx?ItemID=470">Robert D. Schreiber, PhD</a>, alumni endowed professor of pathology an immunology, professor of molecular microbiology, and director of the Center for Human Immunology and Immunotherapy Programs at Washington University School of Medicine in St. Louis. His award lecture was titled, “Cancer Immunoediting&#58; Applying Mechanistic Insights to Cancer Immunotherapy.”<br><br>In addition to presenting a 50-minute lecture at the AACR Annual Meeting 2015, the recipient will receive an honorarium of $10,000.<br><br></p><ul><li>Nominations for these awards must be submitted by 4 p.m. ET, Wednesday, Sept. 3, 2014.</li></ul><p></p><ul><li>For more information, contact Monique P. Eversley at <a href="mailto&#58;"></a> or visit <a href="/Research/Awards/Pages/Awards-Listing.aspx">http&#58;// </a></li></ul><p></p></div>
Nominations Open for 2015 Pezcoller-AACR International Award2313888/18/2014 2:25:19 PM60 Releases/AllItems.aspx584False2014-08-15T04:00:00Z<div class="ExternalClass4DF8605E647C446388358728B43C61E8"><p>​PHILADELPHIA — The American Association for Cancer Research (AACR) announces a call for nominations for the 18th annual Pezcoller Foundation-AACR International Award for Cancer Research.<br><br>The awards will be presented during the <a href="/Meetings/Pages/MeetingDetail.aspx?EventItemID=25">AACR Annual Meeting 2015</a>, which will be held April 18-22, in Philadelphia.<br><br>The <a href="/Research/Awards/Pages/Awards-Detail.aspx?ItemId=16">Pezcoller Foundation-AACR International Award</a> was established in 1997 to recognize a scientist of international renown who has made a major scientific discovery in basic cancer research or who has made significant contributions to translational cancer research, who continues to be active in cancer research and has a record of recent, noteworthy publications, and whose ongoing work holds promise for continued substantive contributions to progress in the field of cancer.<br><br>Last year’s award was presented to <a href="/Newsroom/Pages/News-Release-Detail.aspx?ItemID=476">Elaine Fuchs, PhD</a>, Rebecca C. Lancefield professor and head of the Laboratory of Mammalian Cell Biology and Development at The Rockefeller University in New York. Her lecture was titled, “Stem Cells in Science, Action, and Cancer.”<br><br>In addition to the 50-minute award lecture presented at the AACR Annual Meeting 2015, the recipient will receive an honorarium of 75,000 euros. The recipient will also present the 10th annual Stanley J. Korsmeyer Lecture at the Venetian Institute for Molecular Medicine in Padua, Italy, prior to the Pezcoller Foundation’s official award ceremony in Trento, Italy, May 2015.<br><br></p><ul><li>Nominations for this award must be submitted by 4 p.m. ET, Wednesday, Sept. 10, 2014.</li></ul><p></p><ul><li>For more information, contact Monique P. Eversley at <a href="mailto&#58;" target="_blank"></a> or visit <a href="/Research/Awards/Pages/Awards-Listing.aspx">http&#58;//</a>.</li></ul><p></p></div>
NSAIDs May Lower Breast Cancer Recurrence Rate in Overweight and Obese Women2205398/14/2014 1:17:43 PM111 Releases/AllItems.aspx582False2014-08-14T04:05:00Z<div class="ExternalClass7EA47BFD999049BCBA003C2480B52607"><p>PHILADELPHIA — Recurrence of hormone-related breast cancer was cut by half in overweight and obese women who regularly used aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs), according to data published in <em><a href="http&#58;//" target="_blank">Cancer Research</a></em>, a journal of the American Association for Cancer Research. <img alt="Linda A. deGraffenried, PhD" src="/PublishingImages/deGraffenried_Linda_150x200.jpg" style="margin&#58;10px;float&#58;right;vertical-align&#58;auto;" /></p><p>“Our studies suggest that limiting inflammatory signaling may be an effective, less toxic approach to altering the cancer-promoting effects of obesity and improving patient response to hormone therapy,” said <a href="http&#58;//" target="_blank">Linda A. deGraffenried, PhD</a>, associate professor of nutritional sciences at The University of Texas in Austin.</p><p>The study found that women whose body mass index (BMI) was greater than 30 and had estrogen receptor alpha (ERα)-positive breast cancer had a 52 percent lower rate of recurrence and a 28-month delay in time to recurrence if they were taking aspirin or other NSAIDs.</p><p>“These results suggest that NSAIDs may improve response to hormone therapy, thereby allowing more women to remain on hormone therapy rather than needing to change to chemotherapy and deal with the associated side effects and complications,” said deGraffenried. “However, these results are preliminary and patients should never undertake any treatment without consulting with their physician.”</p><p>Using blood from obese patients, deGraffenried and colleagues conducted experiments in the laboratory to recreate a tumor environment containing cancer cells, fat cells, and the immune cells that promote inflammation. They found that the factors associated with obesity initiate a network of signaling within the tumor environment to promote growth and resistance to therapy.</p><p>“These studies show that the greatest benefit from aspirin [and other NSAIDs] will be in those with a disease driven by inflammation, and not just obesity,” explained DeGraffenried.</p><p>Researchers used data from 440 women diagnosed with invasive, ERα-positive breast cancer and treated at The University of Texas Health Science Center and the START Center for Cancer Care clinic, both in San Antonio, Texas, between 1987 and 2011.</p><p>Of the women studied, 58.5 percent were obese and 25.8 percent were overweight. About 81 percent took aspirin, and the rest took another NSAID. About 42 percent and 25 percent took statins and omega-3 fatty acid, respectively.</p><p>There was an indication of protection from aspirin and other NSAIDs even after controlling for statins and omega-3 fatty acid use, which also have anti-inflammatory effects.</p><p>This study was funded by the U.S. Department of Defense, the Breast Cancer Research Program of the Congressionally Directed Medical Research Programs, and the National Cancer Institute. DeGraffenried declares no conflicts of interest.​</p></div>
Leading Cancer Organizations Urge FDA to Regulate All Tobacco Products2122548/11/2014 8:34:40 PM130 Releases/AllItems.aspx581False2014-08-11T20:30:00ZAACR, ASCO Issue Joint Response to Proposed Rule<div class="ExternalClassA08FD0B6C4844AE0B236013BCC9935F3"><p>PHILADELPHIA — The American Association for Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO), in a joint letter responding to a proposal by the U.S. Food and Drug Administration (FDA) to extend its regulatory authority over tobacco products, today urged the agency to regulate electronic cigarettes (e-cigarettes), cigars, and all other tobacco products and to strengthen the proposed regulations for newly deemed products. </p><p>“There is no safe form of tobacco use,” said Margaret Foti, PhD, MD (hc), chief executive officer of the AACR. “Tobacco is the leading cause of preventable deaths in the United States, and among its dire health consequences are 18 different types of cancer. It is imperative that the FDA takes action to regulate all tobacco products. The future health of the American people, in particular our nation’s children, depends on it.”</p><p>The AACR and ASCO applauded the FDA’s proposal to regulate e-cigarettes. “We believe it is vitally important for the FDA to begin regulating these products, especially because we don’t know much about the health effects of e-cigarette use. We are also quite concerned that e-cigarettes may increase the likelihood that nonsmokers or former smokers will use combustible tobacco products or that they will discourage smokers from quitting,” said Peter P. Yu, MD, FASCO, president of ASCO. </p><p>“There are insufficient data on the long-term health consequences of e-cigarettes, their value as tobacco cessation aids, or their effects on the use of conventional cigarettes. Any benefits of e-cigarettes are most likely to be realized in a regulated environment in which appropriate safeguards can be implemented,” said Roy S. Herbst, MD, PhD, chair of the AACR Tobacco and Cancer Subcommittee and chief of medical oncology at Yale Comprehensive Cancer Center. </p><p>The AACR and ASCO support many of the FDA’s proposals for regulating e-cigarettes and other products, but urge the agency to do more. Specifically, preventing children from using tobacco products is crucial and can be achieved by efforts such as banning youth-oriented advertising and marketing, self-service product displays, and tobacco company sponsorship of youth-oriented events, in addition to restricting sales to minors and implementing age-verification procedures for internet sales.</p><p>Expressing grave concern about the proliferation of flavored e-cigarettes, the AACR and ASCO encouraged the agency to ban e-cigarette flavors or flavor names that are brand names of candy, cookies, soda, and other such products, and to prohibit e-cigarettes containing candy and other youth-friendly flavors, unless there is evidence demonstrating that they do not encourage young people to use these products.</p><p>The AACR and ASCO strongly discouraged the FDA from exempting “premium” cigars from regulation, an option the agency is considering. “All cigars pose serious health risks,” said Graham Warren, MD, PhD, chair of ASCO’s Tobacco Cessation and Control Subcommittee. “As the FDA itself noted in the proposed rule, even cigar smokers who do not inhale have a seven to 10 times higher overall risk of mouth and throat cancer compared with individuals who have never smoked. Exempting these dangerous products from FDA regulation is clearly not in the best interest of public health.”</p><p>Noting that both large and small cigars are of increasing interest to youth and adult users, the AACR and ASCO underscored that the continued availability of premium cigars in an unregulated market, compounded with the ability of the tobacco industry to strategically market its products to youths and young adults, could reverse the progress made in reducing youth tobacco use.</p><p>Finally, the AACR and ASCO urged the FDA to drop the “consumer surplus” discount used to assess the net impact of the proposed deeming rule. This discount allows the FDA to only consider 30 percent of the benefits achieved via tobacco cessation due to the costs associated with this proposed regulation, including the “lost pleasure” of smoking. The AACR and ASCO stressed that addiction is an unwelcome burden for many tobacco users and that many consumers are not making rational and fully informed choices when initiating and continuing their use of tobacco products.</p><p><a href="/AdvocacyPolicy/GovernmentAffairs/Documents/AACR%20ASCO%20Comments%20on%20FDA%20Proposed%20Tobacco%20Deeming%20Rule-FINAL.pdf" target="_blank">Read</a> the joint AACR and ASCO letter to the FDA ​(<a href="http&#58;//" target="_blank">Adobe Reader</a> required).</p></div>
Postmenopausal Breast Cancer Risk Decreases Rapidly After Starting Regular Physical Activity2105948/11/2014 9:10:27 PM121 Releases/AllItems.aspx580False2014-08-11T04:00:00ZBenefits quickly disappear if regular physical activity stops<div class="ExternalClassEEC7D7EC739948A4AD05CDFB7BEBCA08"><p>​PHILADELPHIA — Postmenopausal women who in the past four years had undertaken regular physical activity equivalent to at least four hours of walking per week had a lower risk for invasive breast cancer compared with women who exercised less during those four years, according to data published in <a href="http&#58;//" target="_blank">Cancer Epidemiology, Biomarkers &amp; Prevention</a>, a journal of the American Association for Cancer Research.</p><p>&quot;Twelve MET-h [metabolic equivalent task-hours] per week corresponds to walking four hours per week or cycling or engaging in other sports two hours per week and it is consistent with the World Cancer Research Fund recommendations of walking at least 30 minutes daily,&quot; said Agnès Fournier, PhD<img alt="Agnès Fournier, PhD" src="/PublishingImages/Fournier_Agnes_150x200.jpg" style="margin&#58;10px;vertical-align&#58;auto;float&#58;right;" />, a researcher in the <a href="https&#58;//" target="_blank">Centre for Research in Epidemiology and Population Health</a> at the Institut Gustave Roussy in Villejuif, France. &quot;So, our study shows that it is not necessary to engage in vigorous or very frequent activities; even walking 30 minutes per day is beneficial.&quot;</p><p>Postmenopausal women who in the previous four years had undertaken 12 or more MET-h of physical activity each week had a 10 percent decreased risk of invasive breast cancer compared with women who were less active. Women who undertook this level of physical activity between five and nine years earlier but were less active in the four years prior to the final data collection did not have a decreased risk for invasive breast cancer.</p><p>&quot;Physical activity is thought to decrease a woman's risk for breast cancer after menopause,&quot; said Fournier. &quot;However, it was not clear how rapidly this association is observed after regular physical activity is begun or for how long it lasts after regular exercise stops.</p><p>&quot;Our study answers these questions,&quot; Fournier continued. &quot;We found that recreational physical activity, even of modest intensity, seemed to have a rapid impact on breast cancer risk. However, the decreased breast cancer risk we found associated with physical activity was attenuated when activity stopped. As a result, postmenopausal women who exercise should be encouraged to continue and those who do not exercise should consider starting because their risk of breast cancer may decrease rapidly.&quot;</p><p>Fournier and colleagues analyzed data obtained from biennial questionnaires completed by 59,308 postmenopausal women who were enrolled in E3N, the French component of the European Prospective Investigation Into Cancer and Nutrition (EPIC) study. The mean duration of follow-up was 8.5 years, during which time, 2,155 of the women were diagnosed with a first primary invasive breast cancer.</p><p>The total amount of self-reported recreational physical activity was calculated in MET-h per week. The breast cancer risk-reducing effects of 12 or more MET-h per week of recreational physical activity were independent of body mass index, weight gain, waist circumference, and the level of activity from five to nine years earlier.&#160;</p><p>This study was supported by funds from Institut National du Cancer, the Fondation de France, and the Institut de Recherche en Santé Publique. The E3N cohort is financially supported by the Institut National du Cancer, the Mutuelle Générale de l'Education Nationale, the Institut de Cancérologie Gustave Roussy, and the Institut National de la Santé et de la Recherche Médicale. Fournier declares no conflicts of interest.</p></div>
Cancer Discovery Impact Factor Increases Nearly 60 Percent Over Prior Year2035608/8/2014 8:15:01 PM136 Releases/AllItems.aspx579False2014-08-08T20:05:00ZNewest Impact Factor is 15.929 compared to10.143 last year<div class="ExternalClass573AD6DF56194702B69AAB3BCF6DECEE"><p>PHILADELPHIA — <em>Cancer Discovery</em>, a journal of the American Association for Cancer Research (AACR), reported an Impact Factor of 15.929 in 2014, which is a 57 percent increase over the 10.143 Impact Factor from 2013.</p><p>The journal ranked sixth out of 202 oncology journals, according to the latest <em>Journal Citation Report</em> from Thomson Reuters, the industry standard for journal impact measurement. </p><p><em>Cancer Discovery</em> is co-led by editors-in-chief Lewis C. Cantley, PhD, director of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medical College in New York and José Baselga, MD, PhD, physician-in-chief at Memorial Sloan Kettering Cancer Center in New York. </p><p>“The AACR is thrilled that the <em>Cancer Discovery</em> Impact Factor has increased so significantly this year,” said Margaret Foti, PhD, MD (hc), chief executive officer of the AACR. “This shows that we are continuing to meet our goal of providing a publication outlet that captures the most compelling work across the breadth of the cancer research field. It is also a testament to the hard work and commitment of Drs. Cantley and Baselga, the co-editors-in-chief of the journal, and our expert scientific editors.” </p><p><em>Cancer Discovery</em> publishes high-impact, peer-reviewed articles describing major advances in basic, translational, and clinical research, as well as cancer science news, review articles, perspectives, commentaries, and summaries of other important peer-reviewed journal articles.</p><p><em>Cancer Discovery</em> is one of eight journals published by the AACR. The other journals are <em>Cancer Epidemiology, Biomarkers &amp; Prevention</em>; <em>Cancer Immunology Research</em>; <em>Cancer Prevention Research</em>; <em>Cancer Research</em>; <em>Clinical Cancer Research</em>; <em>Molecular Cancer Research</em>; and <em>Molecular Cancer Therapeutics</em>.</p><p>Read more information on <a href="http&#58;//" target="_blank"><em>Cancer Discovery</em>. ​</a></p></div>
American Association for Cancer Research Journals Receive Top Rankings in 2014 Report2035588/8/2014 8:10:51 PM129 Releases/AllItems.aspx578False2014-08-08T20:00:00Z<div class="ExternalClass663FC918623D470C9BC58D817A7F72AC"><p>PHILADELPHIA — The journals of the American Association for Cancer Research (AACR) ranked in the top 25 percent of all oncology journals with regard to Impact Factor, according to the latest <em>Journal Citation Report </em>from Thomson Reuters, the industry-standard measurement report. </p><p>The overall journals program of the AACR saw year-to-year increases in Impact Factor and total citations, according to the report. The report measured seven AACR journals. It did not measure <em>Cancer Immunology Research </em>due to its recent launch. </p><p>AACR journals received almost 18 percent of all citations in the oncology specialty. </p><p>Three of the AACR journals—<em>Cancer Discovery</em>, <em>Cancer Research</em>, and <em>Clinical Cancer Research</em>—ranked in the top 6 percent by Impact Factor (of 202 oncology journals measured by Thomson Reuters).</p><p>For the 18th consecutive year, <em>Cancer Research </em>ranked first among oncology journals in the number of total citations, with approximately 143,000. <em>Cancer Research</em> ranks 21st in total citations among all 8,474 journals measured by Thomson Reuters. </p><p><em>Clinical Cancer Research</em> ranked third in total citations among oncology journals, with more than 68,000 citations. </p><p>“We are delighted by the results of this report, which show that the AACR’s portfolio of peer-reviewed journals continues to be an authoritative source of information across the breadth of the cancer research field,” said Margaret Foti, PhD, MD (hc), chief executive officer of the AACR. “The positive performance of our peer-reviewed journals is a result of the expertise and hard work of our scientific editors who give generously of their time and wisdom, as well as that of our staff. The AACR is committed to continuing to foster the exchange of high-quality, innovative research findings among scientists, which is vital to accelerating the pace of progress toward the prevention and cure of cancer.”</p><p><a href="http&#58;//" target="_blank">View</a> the complete journal ranking information. </p><p>The eight journals of the AACR are <em>Cancer Discovery</em>; <em>Cancer Epidemiology, Biomarkers &amp; Prevention</em>; <em>Cancer Immunology Research</em>; <em>Cancer Research</em>; <em>Cancer Prevention Research</em>; <em>Clinical Cancer Research</em>; <em>Molecular Cancer Research</em>; and <em>Molecular Cancer Therapeutics</em>. </p></div>
Gut Microbiome Analysis Improved Noninvasive Colorectal Cancer Screening1992498/7/2014 1:49:58 PM171 Releases/AllItems.aspx577False2014-08-07T04:05:00Z<div class="ExternalClassAA43AD2F0D9840DAB1798B8402644E96"><p>PHILADELPHIA — Analysis of the gut microbiome more successfully distinguished healthy individuals from those with precancerous adenomatous polyps and those with invasive colorectal cancer compared with assessment of clinical risk factors and fecal occult blood testing, according to data published in <em><a href="http&#58;//" target="_blank">Cancer Prevention Research</a></em>, a journal of the American Association for Cancer Research.</p><p>“A person’s gut microbiome is the collection of all the bacteria in their gut,” said <a href="http&#58;//" target="_blank">Patrick D. Schloss, PhD</a>, associate professor in the <a href="http&#58;//" target="_blank">Department of Microbiology and Immunology</a> at the University of Michigan in Ann Arbor. “The number of bacteria in the gut is huge; it outnumbers the number of cells in our bodies 10 to one, and the diversity of the bacteria present is critical to our health. By sequencing the V4 region of the 16S rRNA gene we were able to identify the bacteria present in each individual’s gut microbiome.</p><p>“We found that the composition of the gut microbiome allowed us to identify who in our study had precancerous adenomatous polyps and who had invasive colorectal cancer,” continued Schloss. “If our results are confirmed in larger groups of people, adding gut microbiome analysis to other fecal tests may provide an improved, noninvasive way to screen for colorectal cancer.”</p><p>By analyzing stool samples from 90 individuals—30 healthy individuals, 30 patients with precancerous adenomatous polyps, and 30 patients with invasive colorectal cancer—Schloss and his colleagues established that the composition of the gut microbiome was different for individuals in the three groups. </p><p>Using this information, they identified gut microbiome signatures for each group. Adding analysis of these signatures to assessment of age and race, which are clinical risk factors for precancerous adenomatous polyps, improved prediction of the presence of precancerous adenomatous polyps 4.5-fold. Adding analysis of the gut microbiome signatures to assessment of age, race, and body mass index (BMI), which are clinical risk factors of invasive colorectal cancer, improved prediction of the presence of invasive colorectal cancer 5.4-fold. </p><p>In addition, analysis of the gut microbiome signatures was better than fecal occult blood testing at distinguishing individuals with precancerous adenomatous polyps from those with invasive colorectal cancer (AUC=0.617 and AUC=0.952, respectively). Assessing BMI, fecal occult blood test results, and gut microbiome signatures together further improved the ability to distinguish between the two conditions (AUC=0.969).</p><p>“Our data show that gut microbiome analysis has the potential to be a new tool to noninvasively screen for colorectal cancer,” said Schloss. “We don’t think that this would ever replace other colorectal cancer screening approaches, rather we see it as complementary.</p><p>“The study involved not just microbiologists but also researchers skilled in statistics, genomics, and epidemiology,” continued Schloss. “Its success shows just how important interdisciplinary science is.”</p><p>This study was supported by funds from the National Institutes of Health. Schloss declares no conflicts of interest.​</p></div>